Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes

  1. Kristin M David1,
  2. Jonathan A Morris1,
  3. Bettina J Steffen1,
  4. Kathy S Chi-Burris1,
  5. Vincent P Gotz1,
  6. Robert D Gordon2

Article first published online: 14 FEB 2005

DOI: 10.1111/j.1399-0012.2005.00338.x

Issue

Clinical Transplantation

Clinical Transplantation

Volume 19, Issue 2, pages 279–285, April 2005

Additional Information

How to Cite

David, K. M., Morris, J. A., Steffen, B. J., Chi-Burris, K. S., Gotz, V. P. and Gordon, R. D. (2005), Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clinical Transplantation, 19: 279–285. doi: 10.1111/j.1399-0012.2005.00338.x

Author Information

  1. 1

     ProSanos Corporation, La Jolla, CA

  2. 2

     Roche Laboratories, Nutley, NJ, USA

*Kristin David, ProSanos Corp., 7590 Fay Avenue, Suite 204, La Jolla, CA 92037, USA. Tel.: 858 456 5223; fax: 858 456 5001; e-mail: kristin.david@prosanos.com

Publication History

  1. Issue published online: 1 MAR 2005
  2. Article first published online: 14 FEB 2005
  3. Accepted for publication 21 December 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (160K)

Keywords:

  • azathioprine;
  • diabetes mellitus;
  • kidney transplantation;
  • mycophenolate mofetil

Abstract:  Outcomes specifically in mycophenolate mofetil (MMF)-treated diabetic renal transplant patients have not been previously reported. This study compared acute rejection (AR), late acute rejection (LAR), patient survival [and specifically death from cardiovascular (CV), infectious and malignant causes], incidence of post-transplant malignancies, and graft loss in MMF- or azathioprine (AZA)-treated renal transplant patients with pre-transplant diabetes. Outcomes were compared between MMF- (n = 14 144) and AZA- (n = 3001) treated diabetic patients using the Scientific Registry of Transplant Recipients data on all U.S. adult renal transplants performed between 1995 and 2002. Statistical analyses included Kaplan–Meier survival analysis, Cox multivariable regression and chi-square tests. MMF patients had less AR compared with AZA-treated patients (23.5% vs. 28.3%, p < 0.001) and less risk for LAR over 4 yr [hazard ratio (HR): 0.64, 95% CI 0.44, 0.92; p = 0.02]. While time to any-cause death did not differ between the groups, MMF treatment was associated with a 20% decreased risk of CV death (HR: 0.80, 95% CI 0.67, 0.97; p = 0.020) compared with AZA treatment. MMF patients also had a lower incidence of malignancies than AZA patients (2.2% vs. 3.7%, p < 0.001). These results suggest treatment with MMF compared with treatment with AZA in diabetic transplant patients is associated with less AR, less risk of LAR, a decreased risk of CV death, and a lower incidence of malignancies.

View Full Article (HTML) Get PDF (160K)